Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Acute myeloid leukemia (AML) is a heterogeneous malignant disease characterized by the accumulation of immature myeloid progenitor cells, which leads to anemia, thrombocytopenia and impaired immunity. Treatment with intensive chemotherapy regimens of adult AML patients who are 60 years of age or younger results in hematologic remission in about 70-90% of patients, but at least 30% of these patients will experience a relapse [1]. Remaining cells in the bone marrow after chemotherapy treatment are thought to be responsible for the relapse.

Source: Leukemia Research - November 27, 2018 Category: Hematology Authors: Rik A. Brooimans, Vincent H.J. van der Velden, Nancy Boeckx, Jennita Slomp, Frank Preijers, Jeroen G. te Marvelde, Ngoc M. Van, Antoinette Heijs, Erik Huys, Bronno van der Holt, Georgine E. de Greef, Angele Kelder, Gerrit Jan Schuurhuis Tags: Research paper Source Type: research